Overview

Ketamine and Epigenetic Aging

Status:
Recruiting

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

This is a prospective, clinical pilot study (n=20) to evaluate the impact of a ketamine treatment for Major Depressive Disorder (MDD) or Post Traumatic Stress Disorder (PTSD) on epigenetic aging by the TruAge epigenetic age laboratory test.

Phase:

Phase 2

Details

Lead Sponsor:

TruDiagnostic

Collaborator:

Wild Health

Treatments:

Ketamine